PARP-inhibitors: A New Generation of Cancer Drugs
Вставка
- Опубліковано 6 вер 2024
- First of new generation of cancer drugs granted European approval
A new drug for ovarian cancer, developed by researchers at the University of Cambridge and AstraZeneca, has become the first of new class of drugs, known as PARP-inhibitors, to be granted approval anywhere in the world. The drug, Lynparza, has been granted Marketing Authorisation from the European Commission.
www.youtube.com...
The point in understanding if somebody really knows what he is talking about is, that he is able to explain it in a ridiculously easy way, so that everybody can understand it. This in turn makes this Prof., a real man understanding what he is doing.
A really good explanation
A very clear and succinct explanation. Thanks.
Yes, a typical example of the inhibitors in this line is Olaparib. It selectively binds to and inhibits PARP, inhibiting PARP-mediated repair of single strand DNA breaks. PARP inhibition also showed potential in other aspects like enhancing the cytotoxicity of DNA-damaging agents and may reverse tumor cell chemoresistance and radioresistance.
0:34 Please correct me if I'm wrong, on the picture we see 1 chromosome which consists of 2 sister chromatids and they should be identical, BRCAm and BRCAwt should be pictured on 2 homologous chromosomes? Thanks in advance
First! Also, this is a very amazing breakthrough for human civilization.
great news :)
thats great